TEVA, US8816242098

Barclays raises Teva target to USD 47 for Teva stock

Published on 10/16/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays lifted its target to USD 47 on October 15, 2026. Teva stock heads toward November 3 results after USD 4.14 billion in second-quarter revenue.

Pipeline milestones and dates

Barclays raised its Teva target from USD 42.00 to USD 47.00 on October 15, 2026.
Weltruza received FDA approval on October 9, 2026, with three available strengths.
Teva is scheduled to report third-quarter results on November 3, 2026, and hold its R&D Day on November 11, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Limited (ISIN US8816242098) received a higher Barclays valuation on October 15, 2026, when the bank lifted its price target from USD 42.00 to USD 47.00. Markets Insider reported that Barclays kept its Overweight rating in a third-quarter earnings preview.

Weltruza adds a pipeline milestone

The most recent operating catalyst was Teva's October 9, 2026, U.S. approval for Weltruza, a once-monthly injectable olanzapine treatment for adults with schizophrenia. The company said the product will launch in three strengths, 318 mg, 425 mg and 531 mg, with no loading dose, oral supplementation or post-injection monitoring required. GlobeNewswire carried Teva's announcement.

For the second quarter of 2026, Teva reported revenue of USD 4.14 billion, according to MarketBeat. That result gives the upcoming report a concrete benchmark, while the new target compares with Barclays' earlier USD 42.00 level.

What dates matter for the next update?

Teva's chronology points to three milestones: on September 23, 2026, the company set its third-quarter results release for 7:00 a.m. ET; on October 9, 2026, it secured the Weltruza approval with three dosage strengths; and on October 15, 2026, Barclays raised its target to USD 47.00. The September schedule came from Teva's investor release, the approval from GlobeNewswire and the target change from Markets Insider.

The next two dated events are the third-quarter results on November 3, 2026, at 7:00 a.m. ET, followed by Teva's R&D Day on November 11, 2026. Teva announced the results timetable, while the company's event notice sets the R&D Day date and identifies the pipeline as its subject. Teva said presentations will begin at 8:30 a.m. ET.

Stock valuation stays near the yearly high

The latest U.S. quote was last at USD 41.11 on October 15, 2026, at 4:00 p.m. ET on the NYSE. Teva's market capitalization was USD 47.9 billion as of October 16, 2026, and its 52-week range was USD 18.83 to USD 42.02 as of October 15, 2026. The pipeline approval, the higher Barclays target and the November dates give investors three measurable reference points for the next update.